January 2026 in “RSC Advances” The hydrogel helps heal wounds without scars by releasing two drugs gradually.
2 citations
,
February 2024 in “Medicine” A mutation in the IL2RA gene increases the risk of alopecia areata.
77 citations
,
April 2016 in “British journal of dermatology/British journal of dermatology, Supplement” IL-17 is a key target for treating inflammatory skin diseases, especially psoriasis.
221 citations
,
June 1992 in “Proceedings of the National Academy of Sciences” Interleukin 6 may help protect skin without causing inflammation.
January 2024 in “Wiadomości Lekarskie” DEC cells show promise as a safe and effective treatment for Duchenne muscular dystrophy.
1 citations
,
October 2022 in “Molecular therapy” The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.
1 citations
,
July 2025 in “Journal of Investigative Dermatology” IL-27 may help prevent hair loss by creating immune-suppressing cells.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
26 citations
,
September 2018 in “Colloids and Surfaces B: Biointerfaces” A new liposome treatment helps heal deep burns on mice by improving hair regrowth and reducing scarring.
4 citations
,
October 2020 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.
38 citations
,
March 2015 in “Journal of controlled release” IMSG nanoparticles improve vaccine delivery and immune response through hair follicles.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
3 citations
,
February 2023 in “Journal of drug delivery science and technology” The new drug carriers show promise for better targeting and treating ovarian cancer.
1 citations
,
November 2025 in “Stem Cell Research & Therapy” Immortalized hair follicle cells could be useful for regenerative medicine and treating inflammation and oxidative stress.
March 2026 in “Bioconjugate Chemistry” Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.
6 citations
,
September 2018 in “International Journal of Molecular Sciences” PRP derivatives are likely safe for therapeutic use without harmful effects.
IL-18 signaling helps mature Tregs move into the thymus.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
Mealworm protein helps fat cell development and may aid in metabolic health and hair growth.
August 2025 in “BMC Pharmacology and Toxicology” The LTF gene may help predict and manage nonspecific orbital inflammation.
1 citations
,
October 2023 in “European Journal of Dermatology” Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.
29 citations
,
November 2014 in “Experimental Dermatology” Injecting alpha-melanocyte-stimulating hormone in mice improved skin healing and reduced scarring.
Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.
7 citations
,
January 2022 in “Biomedicines” Cells from the lower part of hair follicles are a promising, less invasive option for immune system therapies.
April 2016 in “Journal of Investigative Dermatology” Blocking certain proteins can significantly regrow hair in severe alopecia areata.
66 citations
,
December 2014 in “Nature Communications” Fibroblasts can be turned into melanocytes for potential skin treatments.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.